CA1339631C - Process and intermediates for grf peptide - Google Patents
Process and intermediates for grf peptideInfo
- Publication number
- CA1339631C CA1339631C CA000579916A CA579916A CA1339631C CA 1339631 C CA1339631 C CA 1339631C CA 000579916 A CA000579916 A CA 000579916A CA 579916 A CA579916 A CA 579916A CA 1339631 C CA1339631 C CA 1339631C
- Authority
- CA
- Canada
- Prior art keywords
- resin
- hgrf
- leu
- formula
- arg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 34
- 239000000543 intermediate Substances 0.000 title abstract description 7
- 108090000765 processed proteins & peptides Proteins 0.000 title description 11
- 239000012634 fragment Substances 0.000 claims abstract description 39
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 239000011347 resin Substances 0.000 claims description 133
- 229920005989 resin Polymers 0.000 claims description 133
- -1 2,6-dichloro-benzyl Chemical group 0.000 claims description 33
- 238000005859 coupling reaction Methods 0.000 claims description 29
- 125000006239 protecting group Chemical group 0.000 claims description 29
- 230000008878 coupling Effects 0.000 claims description 26
- 238000010168 coupling process Methods 0.000 claims description 26
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 claims description 14
- 125000000539 amino acid group Chemical group 0.000 claims description 13
- 238000006303 photolysis reaction Methods 0.000 claims description 10
- 230000015843 photosynthesis, light reaction Effects 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 claims description 4
- 229910052698 phosphorus Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 abstract description 17
- 239000007790 solid phase Substances 0.000 abstract description 5
- 101710142969 Somatoliberin Proteins 0.000 abstract description 3
- 238000010647 peptide synthesis reaction Methods 0.000 abstract description 3
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 abstract 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 abstract 1
- HGJRMXOWUWVUOA-GVXVVHGQSA-N Val-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N HGJRMXOWUWVUOA-GVXVVHGQSA-N 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- 229940024606 amino acid Drugs 0.000 description 27
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 20
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 15
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 230000000875 corresponding effect Effects 0.000 description 11
- 125000006850 spacer group Chemical group 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
- 229940116441 divinylbenzene Drugs 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 210000004899 c-terminal region Anatomy 0.000 description 8
- 238000010511 deprotection reaction Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- 150000008064 anhydrides Chemical class 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 102000018997 Growth Hormone Human genes 0.000 description 6
- 108010051696 Growth Hormone Proteins 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- 239000000122 growth hormone Substances 0.000 description 6
- YYTWEEOFRNSTKS-UHFFFAOYSA-N n,n'-dicyclohexylmethanediimine;1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1.C1CCCCC1N=C=NC1CCCCC1 YYTWEEOFRNSTKS-UHFFFAOYSA-N 0.000 description 6
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 6
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000004470 DL Methionine Substances 0.000 description 4
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 235000013372 meat Nutrition 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 235000006109 methionine Nutrition 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000010532 solid phase synthesis reaction Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 3
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 125000001151 peptidyl group Chemical group 0.000 description 3
- 235000003270 potassium fluoride Nutrition 0.000 description 3
- 239000011698 potassium fluoride Substances 0.000 description 3
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- JEQDSBVHLKBEIZ-REOHCLBHSA-N (2s)-2-chloropropanoyl chloride Chemical compound C[C@H](Cl)C(Cl)=O JEQDSBVHLKBEIZ-REOHCLBHSA-N 0.000 description 2
- UHPQFNXOFFPHJW-UHFFFAOYSA-N (4-methylphenyl)-phenylmethanamine Chemical compound C1=CC(C)=CC=C1C(N)C1=CC=CC=C1 UHPQFNXOFFPHJW-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- WBLIXGSTEMXDSM-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH2] WBLIXGSTEMXDSM-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- 229940073584 methylene chloride Drugs 0.000 description 2
- WHQSYGRFZMUQGQ-UHFFFAOYSA-N n,n-dimethylformamide;hydrate Chemical compound O.CN(C)C=O WHQSYGRFZMUQGQ-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 2
- 239000005297 pyrex Substances 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
- ZYNOWVKSWBXQCO-UHFFFAOYSA-N 2-[4-(2-chloropropanoyl)phenoxy]acetic acid Chemical compound CC(Cl)C(=O)C1=CC=C(OCC(O)=O)C=C1 ZYNOWVKSWBXQCO-UHFFFAOYSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- HJBLUNHMOKFZQX-UHFFFAOYSA-N 3-hydroxy-1,2,3-benzotriazin-4-one Chemical compound C1=CC=C2C(=O)N(O)N=NC2=C1 HJBLUNHMOKFZQX-UHFFFAOYSA-N 0.000 description 1
- 241000370685 Arge Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 1
- 206010056438 Growth hormone deficiency Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000825742 Homo sapiens Somatoliberin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- ZYLJULGXQDNXDK-GUBZILKMSA-N Leu-Gln-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O ZYLJULGXQDNXDK-GUBZILKMSA-N 0.000 description 1
- MDXGYYOJGPFFJL-QMMMGPOBSA-N N(alpha)-t-butoxycarbonyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)OC(C)(C)C MDXGYYOJGPFFJL-QMMMGPOBSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 1
- 208000036366 Sensation of pressure Diseases 0.000 description 1
- 102100022831 Somatoliberin Human genes 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- GGNALUCSASGNCK-UHFFFAOYSA-N carbon dioxide;propan-2-ol Chemical compound O=C=O.CC(C)O GGNALUCSASGNCK-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229920001577 copolymer Chemical compound 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- BABWHSBPEIVBBZ-UHFFFAOYSA-N diazete Chemical compound C1=CN=N1 BABWHSBPEIVBBZ-UHFFFAOYSA-N 0.000 description 1
- KJOZJSGOIJQCGA-UHFFFAOYSA-N dichloromethane;2,2,2-trifluoroacetic acid Chemical compound ClCCl.OC(=O)C(F)(F)F KJOZJSGOIJQCGA-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- WGWPRVFKDLAUQJ-MITYVQBRSA-N sermorelin Chemical compound C([C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)C1=CC=C(O)C=C1 WGWPRVFKDLAUQJ-MITYVQBRSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002311 subsequent effect Effects 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 238000007864 suspending Methods 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Disclosed herein is an improved process for preparing the amidated fragment of growth hormone releasing factor containing the first 29 amino acids of the N-terminal portion. The process is based on a modified solid phase peptide synthesis using highly purified key intermediates represented by the formulae Tyr-Arg-Lys-Val-Leu-Gly and Gln-Leu-Ser-Ala-Arg-Lys-Leu.
Description
133~631 Process and Intermediates for GRF Peptide Field of the Invention This invention relates to an improved process for preparing an active fragment of human growth hormone releasing factor (hGRF). More specifically, this invention relates to an efficient process for preparing the amidated fragment of hGRF containing the first 29 amino acids of the N-terminal portion thereof, and to intermediates for use in the process.
Background of the Invention hGRF is a linear peptide of 44 amino acids, having an amidated C-terminus. Structure activity studies have shown that amino acids can be deleted for the C-terminal portion of hGRF without loss of intrinsic activity; see, for example. N. Ling et al., Biochem.
Biophys. Res. Commun., 123, 854 (1984). Such studies have led to the conclusion that the amidated fragment containing the first 29 amino acids of the N-terminal portion, which is the product of the process of this invention, is a preferred active fragment since it retains much of the in vitro and in vivo activity of hGRF. This fragment, which according to convention is designated as hGRF(1-29)NH2 has the following structure:
H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Yal-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH
_~ 2 1339~31 The importance and potential use of growth hormone releasing factors, and their active fragments (including human as well as those from other species), have been well documented; for example, see F.X. Coude et al., Trends in Biotechnology, 2, 83 (1984), and A.M. Felix et al., Annu. Rep. Med.
Chem., 20, 185 (1985). These peptides stimulate the release of growth hormone (GH). Thus the peptides are indicated for treating GH deficiencies and for augmenting the desirable effects of GH. More explicitly, the peptides, including hGRF(1-29)NH2, or their therapeutically acceptable salts, are useful for treating growth related disorders due to insufficient production of endogeneous GH in animals, for example prepubertal growth hormone deficiency in humans; for healing wounds; for improving milk production in dairy herds, such as cows and goats;
for improving the quality of meat in meat-producing animals (i.e. increasing the ratio of meat to fat);
for increasing wool growth; and for improving feed efficiency in meat-producing animals and dairy cows.
The peptides also can be used diagnostically to evaluate pituitary function.
Accordingly, there is a need for an efficient process to prepare hGRF(1-29)NH2.
A number of preparations of hGRF(1-29)NH2 has been reported; see, for example, Felix et al., supra. The previously reported syntheses can be classified either as solid phase synthesis or as solution phase synthesis. A typical example of solid phase synthesis of hGRF(1-29)NH2, wherein amino acids are coupled serially to a solid support is described by Ling et al., supra. A typical example of solution synthesis, wherein peptide fragments are coupled in 1~39~3 L
solution is described by K. Ono et al., European patent application 193,910, published September 10, 1986 . Sol id phase synthesis of hGRF(1-29) NH2 is practical only for preparing experimental quantities of the peptide. Processes based on the solution methods for preparing GRF, or its active analogs, see Ono et al., supra, or J. Diaz et al., US patent 4,707,541, November 17, 1987, are more amenable to large scale production; however, they require numerous operati ons and use l arge amounts of solvents.
The present process has the features of being simple, rapid and avoids the use of obnoxious chemicals. It efficiently and economically produces hGRF(1-29)NH2 on a commercial scale and with a purity of greater than 98%. By the particular choice of reaction conditions and highly pure intermediate fragments, the process yields the desired peptide free of significant racemization and troublesome by-products.
Summary of the Invention The process of this invention is directed to the preparation of hGRF(1-29)NH2, represented by formula 1 :
H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2 The process comprises:
(a) stepwise coupling the required amino acid residues to the amino acid-resin of formula H-Gly-S-P
4 133~31 wherein S is a photosensitive spacer and P is a resin to obtain the HGRF(10-15)-resin of formula 2 X-Tyr(W1)-Arg(W2)-Lys(W3)-Val-Leu-Gly-S-P 2 wherein X is an a-amino protective group, preferably t-butyloxycarbonyl, W1 is a protective group for the hydroxyl of Tyr, preferably benzyl or 2,6-dichloro-benzyl, W is a protective group for the guanidino group of Arg, preferably tosyl or nitro, W3is a protective group for the ~-amino group of Lys, preferably 2-chlorobenzyloxycarbonyl or tosyl, and S
and P are as described above; and cleaving the hGRF(10-15)-resin by photolysis to obtain the corresponding hGRF(10-15)0H fragment of formula 3 X-Tyr(W )-Arg(W )-Lys(W )-Val-Leu-Gly-OH 3 wherein X, W1, w2 and W3 are as described above;
(b) stepwise coupling the required amino acid residues to the amino acid-resin of formula H-Leu-S-P wherein S and P are as defined above to obtain the hGRF(16-22)-resin of formula 4 X-Gln-Leu-Ser(W4)-Ala-Arg(W2)-Lys(W3)-Leu-S-P 4 wherein X is an ~-amino protective group, W2, W3, S
and P are as defined above, and W4 is a protective group for the hydroxyl of Ser, preferably benzyl; and cleaving the hGRF(16-22)-resin by photolysis to obtain the corresponding hGRF(16-22)0H fragment of formula 5 X-Gln-Leu-Ser(W4)-Ala-Arg(W2)-Lys(W3)-Leu-OH 5 in which X is an ~-amino protective group and W2, W3, 1339~31 and W are as defined above;
(c) coupling stepwise a hGRF(23-29)-resin of formula H-Leu-Gln-Asp(W5)-Ile-Met-Ser(W4)-Arg(W2)-Q 6 wherei n w2 and W4 are protecti ve groups as defined above, W is a protective group for the ~-carboxyl of Asp, preferably benzyl, 2,6-dichlorobenzyl or cyclohexyl, and Q is a benzhydrylamine type resin, with the previously noted hGRF(16-22)0H fragment of formula 5 and the hGRF(10-15)0H fragment of formula 3, to obtain a hGRF(10-29)-resin of formula 7 X-Tyr(W1)-Arg(W2)-Lys (W3)-Val-Leu-Gly-Gln-Leu-Ser (W4)-Ala-Arg(W2)-Lys (W3)-Leu-Leu-Gln- 7 Asp(W5)-Ile-Met-Ser (W4)-Arg(W2)-Q
wherein X is an a-amino protective group and W1, W2, W3, W4, W5 and Q are as defined above;
(d) sel ectively removing the a-amino protective group of the hGRF-(10-29)-resin to obtain the corresponding hGRF(10-29)-resin of formula 7 wherein X is hydrogen;
(e) coupling stepwise the last-named hGRF(10-29)-res-in with the required amino acid residues to obtain t h e hGRF(1-29)-resin of formula 8 X-Tyr(Wl)-Ala-Asp(W5)-Ala-Ile-Phe-Thr(W6)-Asn-Ser (W4)-Tyr-(W1)-Arg(W2)-Lys (W3)-Val-Leu-Gly-Gln-Leu-Ser(W4)-Ala-Arg(W2)-Lys(W3)-Leu- 8 Leu-Gln-Asp(W5)-Ile-Met-Ser (W4)-Arg(W2)-Q
wherein X is an a-amino protective group, W1, W2, W3, W4, W5 and Q are as def i ned above, and W6 is a 1339~31 protective group for the hydroxyl of Thr, preferably benzyl; and f) deprotecting the hGRF(1-29)-resin of formula 8 to obtain hGRF(1-29)NH2.
The hGRF(10-15)-resin of formula 2 and the hGRF-(16-22)-resin of formula 4 also are included within the scope of this invention.
Details of the Invention The term "residue" with reference to an amino acid means a radical derived from the corresponding a-amino acid by eliminating the hydroxyl of the carboxyl group and one hydrogen of the a-amino group. The term "amino acid residue" can include radicals derived from side chain protected amino acids.
In general, the abbrevi ati ons used herei n for designating the amino acids and the protective groups are based on recommendations of the IUPAC-IUB
Commission on Biochemical Nomenclature, see Biochemistry, 11, 1726-1732 (1972). For instance, Gln, Ala, Gly, Ile, Arg, Asp, Phe, Ser, Leu, Asn, Thr, Lys, Val, Met and Tyr represent the "residues"
of L-glutamine, L-alanine, glycine, L-isol eucine, L-arginine, L-aspartic acid, L-phenylalanine, L-serine, L-leucine, L-asparagine, L-threonine, L-lysine, L-valine, L-methionine and L-tyrosine, respectively.
The term "photosensitive spacer" or "photolabile spacer", designated by the symbol "S", as used herein, means a divalent organic linking unit which, when incorporated into the peptide-resin system, links the first amino acid building block to the resin by orthogonal covalent bonds, the unit or spacer being further characterized in that the bond between the spacer and the first amino acid residue can be cleaved by photolysis to afford the peptide (or the first amino acid residue) with a C-terminal carboxyl. For exampl es of such spacers, see D.H Rich and S.K. Gurwara, Canadian patent 1,108,348, September 1, 1981; J.P. Tam et al., J. Amer. Chem.
Soc., 102, 6117 (1980); F.S Tjoeng and G.A. Heavner, J. Org. Chem., 48, 355 (1983), and J. Gauthier, Canadian patent application, SN 547,394, filed September 21, 1987. When utilized herein, the spacer is first attached to the resin to give the solid support of formula Q-S-P wherein Q is bromo, chloro or iodo, and S and P are as defined herein.
Preferred spacers are represented by the formulae -CH(CH3)CO~OCH2CO- and -CH(CH3)CO~CH 2CO-, when the resin is one of the benzhydrylamine type, and -CH(CH3)CO- when the resin is one of the styrene-divinylbenzene type.
The term "benzhydrylamine type resin", as used herein means a benzhydrylamine resin of the type commonly employed in solid phase peptide synthesis (SPPS).
Such resins include benzhydrylamine resin (BHA) and 4-methylbenzhydrylamine resin.
8 1~3~31 Turning to the process of this invention, one feature is the protection of labile side chain groups of the various amino acid residues with suitable protective groups to prevent a chemical reaction from occurring at those sites until after the completion of the stepwise coupling to produce the hGRF(1-29)resin of formula 8. Another common feature is the protection of the ~-amino group of an amino acid while the free carboxyl group of that reactant is coupled with the free ~-amino group of the second reactant; the ~-amino protective group being one that can be selectively removed to allow the subsequent coupling step to take place at the amino group from which the protective group is removed.
Still another feature involves the preparation by SPPS of protected peptide-resins, i.e. hGRF(10-15)-resin of formula 2 and the hGRF(16-22)resin of formula 4, from which the resin can be cleaved by photolysis to give corresponding ~-amino protected fragments with a free C-terminal carboxyl. These protected fragments, i.e. the fragments of formulae 3 and 5, are generated in a form suitable for suc-cessive coupling by SPPS methodology to the hGRF(23-29)-resin of formula 6. This manner of generation of the individual peptide fragments enables one to purify important intermediate products before coupling, thus decreasing the chances of carrying undesirable impurities through to the final product.
Two types of photochemical resins are employed to generate the protected fragments. In one case, the commercially available copoly(styrene-divinylbenzene) resin is reacted with 2-chloropropionyl chloride in the presence of aluminum chloride under Friedel-Crafts conditions to obtain the photolabile resin 1:~39S31 2-chloropropionyl copoly(styrene-divinylbenzene). In another case, the commercially available benzhydryl-amine (BHA) resin or 4-methylbenzhydrylamine resin was modified by attaching a photosensitive spacer thereto. Preferred spacers have been noted previously. A preferred photochemical resin of the second type is 4-(2-chloropropionyl)phenoxyacetyl BHA
resin. The actual choice of one type of resin is based on the optimized preparation of the various fragments on respective resins.
To initate the preparation of the fragments of formulae 3 and 5, a first amino acid is coupled to the photolabile resin. The preparation of the amino acid-resin is exemplified as follows: An a-amino protected amino acid, e.g. Na-Boc-glycine, is coupled to a solid support of formula Q-S-P wherein Q is bromo, chloro or iodo and S and P are as defined herein in the presence of potassium fluoride or cesium chloride to give the corresponding soid support having an a-amino protected amino acid linked thereto. Thereafter, the a-amino protective group of the latter resin derivative is removed to give the desired amino acid-resin starting material with a free amino group. Thus, the later amino acid-resin serves as the solid component to elaborate the desired fragment-resin by SPPS.
In practice, the desired fragments of formulae 3 and 5 are prepared by stepwise coupling in the desired order the appropriate a-amino protected amino acids to the growing peptide-resin using a modified form of solid phase synthesis. (For a recent review of solid phase synthesis, see J.M. Stewart and J.D. Young, "Solid Phase Peptide Synthesis", 2nd ed, Pierce Chemical Company, Rockford, Illinois, USA, 1984.) More explicitly, the coupling of the amino acid residues is achieved by using dicyclohexylcarbodii-mide (optionally adding 1-hydroxybenzotriazole, 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine or N-hydroxysuccinimide) as the coupling agent, or by employing the "mixed anhydride" activated form of the a-amino protected acids. Another useful agent is benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP), described by B. Castro et al., Tetrahedron Letters, 14, 1219 (1975). Subse-quent coupling of the fragments is achieved using di-cyclohexylcarbodiimide, dicyclohexylcarbodiimide/-1-hydroxybenzotriazole or BOP. Each ~-amino protected amino acid or protected fragment is introduced into the reaction system in a relatively low excess (two molar equivalents). The success of the coupling reaction at each stage is monitored by the ninhydrin reaction as described by E. Kaiser et al., Anal. Biochem., 34, 595 (1970). Removal of the a-amino protective group completes the coupling cycle.
In the instance where the a-amino protective group is a t-butyloxycarbonyl, trifluoroacetic acid in methylene chloride is used to effect deprotection.
The cleavage of the protected peptide-resins of formulae 2 and 4 is achieved by photolysis. The photolysis is accomplished by dissolving or suspend-ing the protected peptide-resin in a photolytically stable liquid medium; for example, dioxane, dimeth-ylformamide, methanol, ethanol or N-methylpyrroli-dine; purging the solution or suspension of the pept-ide-resin with argon or nitrogen to remove any dis-solved oxygen; and then irradiating the suspension or solution with photolytically effective ultraviolet light. In practice, irradiation at a wavelength of 350 nm has been found to be very effective. In this manner, the fragments hGRF(10-15) of formula 3 and hGRF(16-22)0H of formula 5 are obtained with a high degree of purity. Noteworthy at this point is the fact that the aforementioned procedure, based on the - B
11 1339~31 use of photosensitive resins, yields highly pure (295% pure) fragments having a protected N-terminal amine and a free C-terminal carboxyl, rendering them as ideal intermediates for eventual preparation of high quality hGRF(l-Z9)NH2.
The two fragments of formulae 3 and 5 are now coupled successively and in proper order with a hGRF(23-29)-resin to yield the hGRF(10-29)-resin of formula 7.
Standard SPPS techniques are applied both for the preparation of the hGRF(23-29)-resin and the subsequent coupling of the two fragments to the hGRF(23-29)-resin. BHA resin serves as a very practical resin for the preparation of the hGRF-(23-29)-resin. The conditions, which were described previously for achieving in practice the coupling of the amino acid residues for the preparation of the fragments of formulae 3 and 5, apply likewise to the preparation of the hGRF(23-29)-resin and its subsequent coupling with the fragments to give the hGRF(10-29)-resin.
Thereafter, the latter peptide-resin is coupled stepwise and in the order of the amino acid sequence of hGRF with the remaining amino acid residues, using the coupling conditions described hereinbefore, to yield hGRF(1-29)-resin.
Subsequent deprotection of the latter peptide resin yields the desired hGRF(1-29)NH2. The deprotection is readily achieved with hydrogen fluoride which simultaneously removes the side chain protecting groups and cleaves the peptide residue form the resin.
The following examples illustrate further this invention. Abbreviations used in the examples 12 1~39~31 ...
include Boc: t-butyloxycarbonyl; TFA: trifluoroace-ti c aci d; CH2Cl 2: methyl ene chl oride; DIEA:
diisopropylethylamine; DMF: dimethylformamide; EtOH:
ethanol; DCC: N,N'-dicyclohexylcarbodiimide; HOBT:
1-hydroxybenzotri azol e; and MeOH: methanol .
Sol uti on percentages are cal cul ated on a vol ume/vol -ume basis unless stated otherwise. Temperatures refer to the centigrade scale. The following terms are trademarks : Pyrex , Sep Tech, and Vydac .
Example 1 RESINS:
a) Preparation of 2-chloropropionyl copoly(styrene-1% divinylbenzene) resin 2-Chloropropionyl chloride (140ml, 183.12 9, 1.44 moles) was added to a suspension of aluminum chloride (230.0 y, 1.72 moles) in 1,2-dichloroethane (1.6 liters). The mixture was stirred until complete solution occurred. The solution was then added over a 5 min period to a mechanically stirred suspension of copoly(styrene-1% divinylbenzene) resin (200-400 mesh; 1 Kg). The reaction mixture was allowed to stir at room temperature (20-22~) for 4h. The resin was filtered, washed sequentially with MeOH (3x), CH2Cl2 (3x), and EtOH (3x), and then dried to constant weight in a vacuum oven. The dried material (1.20 Kg) was ready for use.
b) Preparation of 4-(2-chloropropionyl)phenoxyacetyl BHA-resin 4-(2-Chloropropionyl)phenoxyacetic acid (8.35 9, 34.5 mmoles) and HOBT (4.66 9, 34.5 mmoles) were dissolved separately in DMF (2 x 40 ml). The two solutions were mixed and the resulting mixture was cooled at 0~ for 20 min. A solution of DCC in CH2Cl2(27.5 ml, 1.256 mmoles/ml) was added to the solution. The mixture of activated acid was stirred for 30 min. at 0~. The free base of benzhydrylamine copoly (sty-rene-1% divinylbenzene) resin (200-400 mesh, 50.0 9, amine content = 0.46 mmole/g) was generated with DIEA
14 133g~31 in CH2Cl2. The resulting resin was stirred in CH2Cl2 (9OOml). The above noted mixture of activated acid was added in one portion to the stirred resin. The resulting mixture was stirred for 20h at room temper-ature. The resin was collected by filtration, washed with DMF (3X), MeOH (3X), CH2Cl2 (3X), EtOH (3X) and finally dried to constant weight in a vacuum oven to yield 54.3 g of resin. The Kaiser test, E. Kaiser et al., Anal. Biochem., 34, 595 (1970), was negative indicating no starting material.
Example 2 BOC-AMINO ACID RESINS:
a) Preparation of 2-(Boc-glycyl)propionyl copoly-(sty rene-1% divinylbenzene) 2-Chloropropionyl copoly(styrene-1% divinylbenzene) resin of Example la (20-400 mesh, 100g) was stirred in DMF at 60~ for lh. Boc-Gly-OH (56.09, 320 mmoles) and anhydrous potassium fluoride (46.00 g, 70 mmoles) were added in portions to the mixture. The resultant mixture was stirred at 60~ for 24 h. The resin was collected by filtration and washed three times each with DMF, DMF-water, water, DMF-water, EtOH, CH2Cl2 and EtOH. The resin was dried in a vacuum oven to yield 115.22 g of the title compound.
Titration with picric acid according to the method of B.F. Gisin, Anal. Chem. Acta, 58, 248 (1972) indicat-ed an amine content of 0.79 mmole/g resin for glycine.
b) Preparation of 2-(Boc-leucyl)propionyl copoly(sty-rene-1% divinylbenzene) By following the procedure of section (a) of this example but replacing Boc-Gly-OH with an equivalent amount of Boc-Leu-OH, 2-(Boc-leucyl)propionyl copoly(styrene-1% divinylbenzene) was obtained.
c) Preparation of 4-[2-(Boc-glycyl)propionyl]phe-noxyacetyl BHA-resin 4-[2-Chloropropionyl)phenoxyacetyl]-BHA resin of Ex-ample lb (15.0 g, 0.32 mmole/g resin was stirred in dry DMF (160 ml) for lh to allow the resin to swell;
then potassium fluoride (2.53 g, 43.2 mmoles) and Boc-Gly-OH (3.36 g, 19.2 mmoles) were added in por-tions to the mixture. The reaction mixture was stirred for 24h at 70~ and then filtered. The col-lected resin was washed three times each with DMF, DMF-H20, H20, dioxane-H20, dioxane, MeOH, CH2C12 and EtOH. The resin was dried to constant weight in a vacuum oven to afford free-flowing granules (14.90 9 ) -Titration with the picric acid indicated an aminocontent of 0.28 mmoles/g for glycine.
1339~31 Example 3 PROTECTED FRAGMENTS:
a) Preparation of hGRH(16-22)-resin fragment, 2-(Boc-Gln-Leu-Ser(Bzl)-Ala-Arg(Tos)-Lys(2-ClZ)-Leu)propionyl copoly(styrene-1% divinylbenzene), and its subsequent cleavage to the corresponding C-terminal carboxyl fragment hGRF(16-22)OH
The Boc-amino acid resin of Example 2b (618 9, amine content: 0.805 mmole/g) was used to form the hGRF-(16-22)-resin fragment by a modification of the solid phase technique of R.B. Merrifield, J. Amer. Chem.
Soc., 85, 2149 (1963). The selected Boc-amino acids were added to the growing peptidyl-resin chain by the DCC-HOBT activated acid method (Lys, Arg, Ser, Gln) or by the symmetrical anhydride method (Ala, Leu).
The DCC-HOBT method comprised adding DCC (2 equiv.) in CH2Cl2 to a cold solution of HOBT (2 equiv.) and the selected Boc-amino acid (2 equiv.) in DMF, stirring the mixture at 0~ for 30 min. and adding the mixture to a suspension of the peptidyl resin in CH2Cl2. The symmetrical anhydride method comprised adding DCC (2 equiv.) in CH2Cl2 to the selected Boc-amino acid (4 equiv.) in CH2Cl2 at 0~, stirring the mixture at 0~ for 30 min, filtering the mixture and adding the filtrate to a suspension of the peptidyl resin in CH2Cl2. The coupling cycle consis-ted of i) deprotection with 30% TFA in CH2Cl2 (twice for 5 min, once for 25 min) (ii) neutralization with 5% DIEA in CH2Cl2 (twice for 3 min) and (iii) coupl-ing by addition of symmetrical anhydride or activated ester corresponding to the selected Boc-amino acid.
Intermediate washes were done successively with 17 1~396~1 CH2Cl2, 50~ isopropanol in CH2Cl2, isopropanol and CH2Cl2. The coupling reactions were monitored by the Kaiser tests and the fluorescamin test, see B.F.
Gisin, supra. The time required to complete the coupling reaction ranged from 4 to 24h . The final product was washed with DMF, CH2Cl2' isopropanol, CH2Cl 2 and EtOH, and then dried under vacuum to give 1217.4 g of the hGRF(16-22)-resin (100% yield, 96%
pure by HPLC).
The latter peptidyl resin was subjected to photolysis as follows: The peptidylresin (300g) was suspended in a mixture of DMF (7.5 l) and EtOH (3.9 l) in a Pyrex vessel. The suspension was purged with argon.
While being subjected to a continuous stream of argon, the suspension was stirred and irradiated at 0~ at a wavelength of 350 nm for 70h. The suspension was filtered. The filtrate was concentrated to dryness under reduced pressure at room temperature.
The residual oil was triturated with anhydrous Et20 to give a white solid. The solid was collected, washed with anhydrous Et20 and dried under vacuum over P205 to give 185 g of the corresponding pro-tected N-terminal, free C-terminal carboxyl segment, hGRF (16-22)OH, (100% yield, 95.4% pure by HPLC).
b) Preparation of hGRF(10-15)-resin fragment, 4-[2-(Boc-Tyr(2,6-diClBzl)-Arg(Tos)-Lys(2-ClZ)-Val-Leu-Gly)propionyl]phenoxyacetyl BHA resin, and its subsequent cleavage to the corresponding C-terminal carboxyl fragment hGRF(10-15)OH
The hGRF(10-15)-resin was assembled with the appropriate Boc-amino acids in the same manner as described for the preceding peptidylresin, using the symmetrical anhydride method (Leu ,Val ) and the DCC-HOBT method (Lys, Arg,Tyr) and the Boc-Amino acid ~ -~ ~ .
1~9~31 resin of Example 2c (574 g, amine content: 0.45 mmole/g) as a starting material. Thus, the hGRF(10-15)-resin (933 g) was obtained (100% yield).
The latter peptidylresin (466 g) was subjected to photolysis in the manner described for the preceding peptidylresin of Example 3a to give 161 g of the cor-responding protected N-terminal, free C-terminal carboxyl segment, hGRF(10-15)0H (87% yield, 97% pure by HPLC).
In the same manner but replacing the Boc-amino acid resin of Example 2c with an equivalent amount of 2-(Boc-glycyl)propionyl copoly(styrene-1% divinylben-zene) of Example 2a, h-GRF(10-15)0H also was obtained.
Example 4 Preparation of protected hGRF(1-29)-resin By following the solid phase technique described in Example 3, the fragment hGRF(23-29) was assembled on a BHA resin. The appropriate Boc-amino acids were coupled by the DCC-HOBT method (Arg, Ser, Gln) or by the symmetrical anhydride method (Met, Ile, Asp, Leu). The t-butylcarbocation scavenger, DL-methion-ine (1% by volume of the scavanger in 30% TFA-CH2Cl2 solution), was used during Boc-deprotection following the coupling of Met, Ile, Asp and Gln, cf. D.
Le-Nguyen et al., J. Chem. Soc. Perkin Trans., 1, 1915 (1987). On completion of coupling the Leu residue to the growing peptide-resin, the resultant h G R F ( 2 3 - 2 9 ) - r e s i n , i . e .
Boc-Leu-Gln-Asp(Chxl)-Ile-Met-Ser(Bzl)-Arg(Tos)-BHA, was coupled serially (DCC-HOBT method) with the pro-1 9 1 ~ 3 '~
tected fragments of hGRF(16-22)OH and hGRF(10-15)OH
of Examples 3a and 3b, respectively. (For the depro-tection steps prior to the latter two couplings, and for all subsequent deprotection steps of this examp-le, DL-methionine was used as a scavenger.) There-after, the resultant hGRF(10-29)-resin was coupled stepwise with the appropriate Boc-amino acids, using the DCC-HOBT method for coupling Ser, Asn and Tyr, and the symmetrical anhydride method for Thr, Phe, Ile, Ala, Met and Asp. Following a final deprotect-ion (30% TFA in CH2Cl2 plus 1% by volume of DL-methi-onine), the protected hGRF(1-29)-resin, i.e. H-Tyr-(2,6-diClBzl)-Ala-Asp(Chxl)-Ala-Ile-Phe-Thr(Bzl)-Asn-Ser(Bzl)-Tyr(2,6-diClBzl)-Arg(Tos)-Lys(2-ClZ)-Val-Leu-Gly-Gln-Leu-Ser(Bzl)-Ala-Arg(Tos)-Lys(2-ClZ)-Leu-Leu-Gln-Asp(Chxl)-Ile-Met-Ser(Bzl)-Arg(Tos)-BHA
(124.45 g, 91% yield) was obtained.
Example 5 Preparation of hGRF(1-29)NH2 A mixture of the preceding protected hGRF(1-29)-resin (75.9g), DL-methionine (7.6 g) and anisole (distil-led, 75ml) was placed under nitrogen (positive pres-sure). The mixture was cooled at -80~ for 10 min (dry ice-isopropanol bath). Anhydrous hydrogen fluoride was distilled slowly into the cooled mixture over a period of about 70 min. The total amount of hydrogen fluoride added to the mixture was 750 ml.
The reaction mixture was stirred at 0~ for lh under nitrogen. Thereafter, a stream of nitrogen was passed immediately over the reaction vessel at 20-22~
until most of the hydrogen fluoride had evaporated.
The residue was dried under high vacuum for 100 min and then extracted with TFA (700 ml). The extract was concentrated to a small volume. Dilution of the concentrate with Et20 afforded a solid. The solid was collected, washed with Et20 and dried under high vacuum to give 44.7 9 of the crude title compound (TFA salt).
A portion of the latter crude product (4.0g) was purified further by HPLC (Sep Tech 1200, 5 x 35 cm;
Vydac ODS, 15-20~ particle size; 300 nm; linear gradient, 100ml/min, solvent A: 0.06% TFA in water, solvent B: 0.06% TFA in acetonitrile). The appropriate fractions were combined. Acetonitrile was removed under vacuum. The residue was lyophi-lized to give hGRF(1-29)NH2 (662 mg, 16.5% yield, 98.4% pure as indicated by HPLC).
Background of the Invention hGRF is a linear peptide of 44 amino acids, having an amidated C-terminus. Structure activity studies have shown that amino acids can be deleted for the C-terminal portion of hGRF without loss of intrinsic activity; see, for example. N. Ling et al., Biochem.
Biophys. Res. Commun., 123, 854 (1984). Such studies have led to the conclusion that the amidated fragment containing the first 29 amino acids of the N-terminal portion, which is the product of the process of this invention, is a preferred active fragment since it retains much of the in vitro and in vivo activity of hGRF. This fragment, which according to convention is designated as hGRF(1-29)NH2 has the following structure:
H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Yal-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH
_~ 2 1339~31 The importance and potential use of growth hormone releasing factors, and their active fragments (including human as well as those from other species), have been well documented; for example, see F.X. Coude et al., Trends in Biotechnology, 2, 83 (1984), and A.M. Felix et al., Annu. Rep. Med.
Chem., 20, 185 (1985). These peptides stimulate the release of growth hormone (GH). Thus the peptides are indicated for treating GH deficiencies and for augmenting the desirable effects of GH. More explicitly, the peptides, including hGRF(1-29)NH2, or their therapeutically acceptable salts, are useful for treating growth related disorders due to insufficient production of endogeneous GH in animals, for example prepubertal growth hormone deficiency in humans; for healing wounds; for improving milk production in dairy herds, such as cows and goats;
for improving the quality of meat in meat-producing animals (i.e. increasing the ratio of meat to fat);
for increasing wool growth; and for improving feed efficiency in meat-producing animals and dairy cows.
The peptides also can be used diagnostically to evaluate pituitary function.
Accordingly, there is a need for an efficient process to prepare hGRF(1-29)NH2.
A number of preparations of hGRF(1-29)NH2 has been reported; see, for example, Felix et al., supra. The previously reported syntheses can be classified either as solid phase synthesis or as solution phase synthesis. A typical example of solid phase synthesis of hGRF(1-29)NH2, wherein amino acids are coupled serially to a solid support is described by Ling et al., supra. A typical example of solution synthesis, wherein peptide fragments are coupled in 1~39~3 L
solution is described by K. Ono et al., European patent application 193,910, published September 10, 1986 . Sol id phase synthesis of hGRF(1-29) NH2 is practical only for preparing experimental quantities of the peptide. Processes based on the solution methods for preparing GRF, or its active analogs, see Ono et al., supra, or J. Diaz et al., US patent 4,707,541, November 17, 1987, are more amenable to large scale production; however, they require numerous operati ons and use l arge amounts of solvents.
The present process has the features of being simple, rapid and avoids the use of obnoxious chemicals. It efficiently and economically produces hGRF(1-29)NH2 on a commercial scale and with a purity of greater than 98%. By the particular choice of reaction conditions and highly pure intermediate fragments, the process yields the desired peptide free of significant racemization and troublesome by-products.
Summary of the Invention The process of this invention is directed to the preparation of hGRF(1-29)NH2, represented by formula 1 :
H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2 The process comprises:
(a) stepwise coupling the required amino acid residues to the amino acid-resin of formula H-Gly-S-P
4 133~31 wherein S is a photosensitive spacer and P is a resin to obtain the HGRF(10-15)-resin of formula 2 X-Tyr(W1)-Arg(W2)-Lys(W3)-Val-Leu-Gly-S-P 2 wherein X is an a-amino protective group, preferably t-butyloxycarbonyl, W1 is a protective group for the hydroxyl of Tyr, preferably benzyl or 2,6-dichloro-benzyl, W is a protective group for the guanidino group of Arg, preferably tosyl or nitro, W3is a protective group for the ~-amino group of Lys, preferably 2-chlorobenzyloxycarbonyl or tosyl, and S
and P are as described above; and cleaving the hGRF(10-15)-resin by photolysis to obtain the corresponding hGRF(10-15)0H fragment of formula 3 X-Tyr(W )-Arg(W )-Lys(W )-Val-Leu-Gly-OH 3 wherein X, W1, w2 and W3 are as described above;
(b) stepwise coupling the required amino acid residues to the amino acid-resin of formula H-Leu-S-P wherein S and P are as defined above to obtain the hGRF(16-22)-resin of formula 4 X-Gln-Leu-Ser(W4)-Ala-Arg(W2)-Lys(W3)-Leu-S-P 4 wherein X is an ~-amino protective group, W2, W3, S
and P are as defined above, and W4 is a protective group for the hydroxyl of Ser, preferably benzyl; and cleaving the hGRF(16-22)-resin by photolysis to obtain the corresponding hGRF(16-22)0H fragment of formula 5 X-Gln-Leu-Ser(W4)-Ala-Arg(W2)-Lys(W3)-Leu-OH 5 in which X is an ~-amino protective group and W2, W3, 1339~31 and W are as defined above;
(c) coupling stepwise a hGRF(23-29)-resin of formula H-Leu-Gln-Asp(W5)-Ile-Met-Ser(W4)-Arg(W2)-Q 6 wherei n w2 and W4 are protecti ve groups as defined above, W is a protective group for the ~-carboxyl of Asp, preferably benzyl, 2,6-dichlorobenzyl or cyclohexyl, and Q is a benzhydrylamine type resin, with the previously noted hGRF(16-22)0H fragment of formula 5 and the hGRF(10-15)0H fragment of formula 3, to obtain a hGRF(10-29)-resin of formula 7 X-Tyr(W1)-Arg(W2)-Lys (W3)-Val-Leu-Gly-Gln-Leu-Ser (W4)-Ala-Arg(W2)-Lys (W3)-Leu-Leu-Gln- 7 Asp(W5)-Ile-Met-Ser (W4)-Arg(W2)-Q
wherein X is an a-amino protective group and W1, W2, W3, W4, W5 and Q are as defined above;
(d) sel ectively removing the a-amino protective group of the hGRF-(10-29)-resin to obtain the corresponding hGRF(10-29)-resin of formula 7 wherein X is hydrogen;
(e) coupling stepwise the last-named hGRF(10-29)-res-in with the required amino acid residues to obtain t h e hGRF(1-29)-resin of formula 8 X-Tyr(Wl)-Ala-Asp(W5)-Ala-Ile-Phe-Thr(W6)-Asn-Ser (W4)-Tyr-(W1)-Arg(W2)-Lys (W3)-Val-Leu-Gly-Gln-Leu-Ser(W4)-Ala-Arg(W2)-Lys(W3)-Leu- 8 Leu-Gln-Asp(W5)-Ile-Met-Ser (W4)-Arg(W2)-Q
wherein X is an a-amino protective group, W1, W2, W3, W4, W5 and Q are as def i ned above, and W6 is a 1339~31 protective group for the hydroxyl of Thr, preferably benzyl; and f) deprotecting the hGRF(1-29)-resin of formula 8 to obtain hGRF(1-29)NH2.
The hGRF(10-15)-resin of formula 2 and the hGRF-(16-22)-resin of formula 4 also are included within the scope of this invention.
Details of the Invention The term "residue" with reference to an amino acid means a radical derived from the corresponding a-amino acid by eliminating the hydroxyl of the carboxyl group and one hydrogen of the a-amino group. The term "amino acid residue" can include radicals derived from side chain protected amino acids.
In general, the abbrevi ati ons used herei n for designating the amino acids and the protective groups are based on recommendations of the IUPAC-IUB
Commission on Biochemical Nomenclature, see Biochemistry, 11, 1726-1732 (1972). For instance, Gln, Ala, Gly, Ile, Arg, Asp, Phe, Ser, Leu, Asn, Thr, Lys, Val, Met and Tyr represent the "residues"
of L-glutamine, L-alanine, glycine, L-isol eucine, L-arginine, L-aspartic acid, L-phenylalanine, L-serine, L-leucine, L-asparagine, L-threonine, L-lysine, L-valine, L-methionine and L-tyrosine, respectively.
The term "photosensitive spacer" or "photolabile spacer", designated by the symbol "S", as used herein, means a divalent organic linking unit which, when incorporated into the peptide-resin system, links the first amino acid building block to the resin by orthogonal covalent bonds, the unit or spacer being further characterized in that the bond between the spacer and the first amino acid residue can be cleaved by photolysis to afford the peptide (or the first amino acid residue) with a C-terminal carboxyl. For exampl es of such spacers, see D.H Rich and S.K. Gurwara, Canadian patent 1,108,348, September 1, 1981; J.P. Tam et al., J. Amer. Chem.
Soc., 102, 6117 (1980); F.S Tjoeng and G.A. Heavner, J. Org. Chem., 48, 355 (1983), and J. Gauthier, Canadian patent application, SN 547,394, filed September 21, 1987. When utilized herein, the spacer is first attached to the resin to give the solid support of formula Q-S-P wherein Q is bromo, chloro or iodo, and S and P are as defined herein.
Preferred spacers are represented by the formulae -CH(CH3)CO~OCH2CO- and -CH(CH3)CO~CH 2CO-, when the resin is one of the benzhydrylamine type, and -CH(CH3)CO- when the resin is one of the styrene-divinylbenzene type.
The term "benzhydrylamine type resin", as used herein means a benzhydrylamine resin of the type commonly employed in solid phase peptide synthesis (SPPS).
Such resins include benzhydrylamine resin (BHA) and 4-methylbenzhydrylamine resin.
8 1~3~31 Turning to the process of this invention, one feature is the protection of labile side chain groups of the various amino acid residues with suitable protective groups to prevent a chemical reaction from occurring at those sites until after the completion of the stepwise coupling to produce the hGRF(1-29)resin of formula 8. Another common feature is the protection of the ~-amino group of an amino acid while the free carboxyl group of that reactant is coupled with the free ~-amino group of the second reactant; the ~-amino protective group being one that can be selectively removed to allow the subsequent coupling step to take place at the amino group from which the protective group is removed.
Still another feature involves the preparation by SPPS of protected peptide-resins, i.e. hGRF(10-15)-resin of formula 2 and the hGRF(16-22)resin of formula 4, from which the resin can be cleaved by photolysis to give corresponding ~-amino protected fragments with a free C-terminal carboxyl. These protected fragments, i.e. the fragments of formulae 3 and 5, are generated in a form suitable for suc-cessive coupling by SPPS methodology to the hGRF(23-29)-resin of formula 6. This manner of generation of the individual peptide fragments enables one to purify important intermediate products before coupling, thus decreasing the chances of carrying undesirable impurities through to the final product.
Two types of photochemical resins are employed to generate the protected fragments. In one case, the commercially available copoly(styrene-divinylbenzene) resin is reacted with 2-chloropropionyl chloride in the presence of aluminum chloride under Friedel-Crafts conditions to obtain the photolabile resin 1:~39S31 2-chloropropionyl copoly(styrene-divinylbenzene). In another case, the commercially available benzhydryl-amine (BHA) resin or 4-methylbenzhydrylamine resin was modified by attaching a photosensitive spacer thereto. Preferred spacers have been noted previously. A preferred photochemical resin of the second type is 4-(2-chloropropionyl)phenoxyacetyl BHA
resin. The actual choice of one type of resin is based on the optimized preparation of the various fragments on respective resins.
To initate the preparation of the fragments of formulae 3 and 5, a first amino acid is coupled to the photolabile resin. The preparation of the amino acid-resin is exemplified as follows: An a-amino protected amino acid, e.g. Na-Boc-glycine, is coupled to a solid support of formula Q-S-P wherein Q is bromo, chloro or iodo and S and P are as defined herein in the presence of potassium fluoride or cesium chloride to give the corresponding soid support having an a-amino protected amino acid linked thereto. Thereafter, the a-amino protective group of the latter resin derivative is removed to give the desired amino acid-resin starting material with a free amino group. Thus, the later amino acid-resin serves as the solid component to elaborate the desired fragment-resin by SPPS.
In practice, the desired fragments of formulae 3 and 5 are prepared by stepwise coupling in the desired order the appropriate a-amino protected amino acids to the growing peptide-resin using a modified form of solid phase synthesis. (For a recent review of solid phase synthesis, see J.M. Stewart and J.D. Young, "Solid Phase Peptide Synthesis", 2nd ed, Pierce Chemical Company, Rockford, Illinois, USA, 1984.) More explicitly, the coupling of the amino acid residues is achieved by using dicyclohexylcarbodii-mide (optionally adding 1-hydroxybenzotriazole, 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine or N-hydroxysuccinimide) as the coupling agent, or by employing the "mixed anhydride" activated form of the a-amino protected acids. Another useful agent is benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP), described by B. Castro et al., Tetrahedron Letters, 14, 1219 (1975). Subse-quent coupling of the fragments is achieved using di-cyclohexylcarbodiimide, dicyclohexylcarbodiimide/-1-hydroxybenzotriazole or BOP. Each ~-amino protected amino acid or protected fragment is introduced into the reaction system in a relatively low excess (two molar equivalents). The success of the coupling reaction at each stage is monitored by the ninhydrin reaction as described by E. Kaiser et al., Anal. Biochem., 34, 595 (1970). Removal of the a-amino protective group completes the coupling cycle.
In the instance where the a-amino protective group is a t-butyloxycarbonyl, trifluoroacetic acid in methylene chloride is used to effect deprotection.
The cleavage of the protected peptide-resins of formulae 2 and 4 is achieved by photolysis. The photolysis is accomplished by dissolving or suspend-ing the protected peptide-resin in a photolytically stable liquid medium; for example, dioxane, dimeth-ylformamide, methanol, ethanol or N-methylpyrroli-dine; purging the solution or suspension of the pept-ide-resin with argon or nitrogen to remove any dis-solved oxygen; and then irradiating the suspension or solution with photolytically effective ultraviolet light. In practice, irradiation at a wavelength of 350 nm has been found to be very effective. In this manner, the fragments hGRF(10-15) of formula 3 and hGRF(16-22)0H of formula 5 are obtained with a high degree of purity. Noteworthy at this point is the fact that the aforementioned procedure, based on the - B
11 1339~31 use of photosensitive resins, yields highly pure (295% pure) fragments having a protected N-terminal amine and a free C-terminal carboxyl, rendering them as ideal intermediates for eventual preparation of high quality hGRF(l-Z9)NH2.
The two fragments of formulae 3 and 5 are now coupled successively and in proper order with a hGRF(23-29)-resin to yield the hGRF(10-29)-resin of formula 7.
Standard SPPS techniques are applied both for the preparation of the hGRF(23-29)-resin and the subsequent coupling of the two fragments to the hGRF(23-29)-resin. BHA resin serves as a very practical resin for the preparation of the hGRF-(23-29)-resin. The conditions, which were described previously for achieving in practice the coupling of the amino acid residues for the preparation of the fragments of formulae 3 and 5, apply likewise to the preparation of the hGRF(23-29)-resin and its subsequent coupling with the fragments to give the hGRF(10-29)-resin.
Thereafter, the latter peptide-resin is coupled stepwise and in the order of the amino acid sequence of hGRF with the remaining amino acid residues, using the coupling conditions described hereinbefore, to yield hGRF(1-29)-resin.
Subsequent deprotection of the latter peptide resin yields the desired hGRF(1-29)NH2. The deprotection is readily achieved with hydrogen fluoride which simultaneously removes the side chain protecting groups and cleaves the peptide residue form the resin.
The following examples illustrate further this invention. Abbreviations used in the examples 12 1~39~31 ...
include Boc: t-butyloxycarbonyl; TFA: trifluoroace-ti c aci d; CH2Cl 2: methyl ene chl oride; DIEA:
diisopropylethylamine; DMF: dimethylformamide; EtOH:
ethanol; DCC: N,N'-dicyclohexylcarbodiimide; HOBT:
1-hydroxybenzotri azol e; and MeOH: methanol .
Sol uti on percentages are cal cul ated on a vol ume/vol -ume basis unless stated otherwise. Temperatures refer to the centigrade scale. The following terms are trademarks : Pyrex , Sep Tech, and Vydac .
Example 1 RESINS:
a) Preparation of 2-chloropropionyl copoly(styrene-1% divinylbenzene) resin 2-Chloropropionyl chloride (140ml, 183.12 9, 1.44 moles) was added to a suspension of aluminum chloride (230.0 y, 1.72 moles) in 1,2-dichloroethane (1.6 liters). The mixture was stirred until complete solution occurred. The solution was then added over a 5 min period to a mechanically stirred suspension of copoly(styrene-1% divinylbenzene) resin (200-400 mesh; 1 Kg). The reaction mixture was allowed to stir at room temperature (20-22~) for 4h. The resin was filtered, washed sequentially with MeOH (3x), CH2Cl2 (3x), and EtOH (3x), and then dried to constant weight in a vacuum oven. The dried material (1.20 Kg) was ready for use.
b) Preparation of 4-(2-chloropropionyl)phenoxyacetyl BHA-resin 4-(2-Chloropropionyl)phenoxyacetic acid (8.35 9, 34.5 mmoles) and HOBT (4.66 9, 34.5 mmoles) were dissolved separately in DMF (2 x 40 ml). The two solutions were mixed and the resulting mixture was cooled at 0~ for 20 min. A solution of DCC in CH2Cl2(27.5 ml, 1.256 mmoles/ml) was added to the solution. The mixture of activated acid was stirred for 30 min. at 0~. The free base of benzhydrylamine copoly (sty-rene-1% divinylbenzene) resin (200-400 mesh, 50.0 9, amine content = 0.46 mmole/g) was generated with DIEA
14 133g~31 in CH2Cl2. The resulting resin was stirred in CH2Cl2 (9OOml). The above noted mixture of activated acid was added in one portion to the stirred resin. The resulting mixture was stirred for 20h at room temper-ature. The resin was collected by filtration, washed with DMF (3X), MeOH (3X), CH2Cl2 (3X), EtOH (3X) and finally dried to constant weight in a vacuum oven to yield 54.3 g of resin. The Kaiser test, E. Kaiser et al., Anal. Biochem., 34, 595 (1970), was negative indicating no starting material.
Example 2 BOC-AMINO ACID RESINS:
a) Preparation of 2-(Boc-glycyl)propionyl copoly-(sty rene-1% divinylbenzene) 2-Chloropropionyl copoly(styrene-1% divinylbenzene) resin of Example la (20-400 mesh, 100g) was stirred in DMF at 60~ for lh. Boc-Gly-OH (56.09, 320 mmoles) and anhydrous potassium fluoride (46.00 g, 70 mmoles) were added in portions to the mixture. The resultant mixture was stirred at 60~ for 24 h. The resin was collected by filtration and washed three times each with DMF, DMF-water, water, DMF-water, EtOH, CH2Cl2 and EtOH. The resin was dried in a vacuum oven to yield 115.22 g of the title compound.
Titration with picric acid according to the method of B.F. Gisin, Anal. Chem. Acta, 58, 248 (1972) indicat-ed an amine content of 0.79 mmole/g resin for glycine.
b) Preparation of 2-(Boc-leucyl)propionyl copoly(sty-rene-1% divinylbenzene) By following the procedure of section (a) of this example but replacing Boc-Gly-OH with an equivalent amount of Boc-Leu-OH, 2-(Boc-leucyl)propionyl copoly(styrene-1% divinylbenzene) was obtained.
c) Preparation of 4-[2-(Boc-glycyl)propionyl]phe-noxyacetyl BHA-resin 4-[2-Chloropropionyl)phenoxyacetyl]-BHA resin of Ex-ample lb (15.0 g, 0.32 mmole/g resin was stirred in dry DMF (160 ml) for lh to allow the resin to swell;
then potassium fluoride (2.53 g, 43.2 mmoles) and Boc-Gly-OH (3.36 g, 19.2 mmoles) were added in por-tions to the mixture. The reaction mixture was stirred for 24h at 70~ and then filtered. The col-lected resin was washed three times each with DMF, DMF-H20, H20, dioxane-H20, dioxane, MeOH, CH2C12 and EtOH. The resin was dried to constant weight in a vacuum oven to afford free-flowing granules (14.90 9 ) -Titration with the picric acid indicated an aminocontent of 0.28 mmoles/g for glycine.
1339~31 Example 3 PROTECTED FRAGMENTS:
a) Preparation of hGRH(16-22)-resin fragment, 2-(Boc-Gln-Leu-Ser(Bzl)-Ala-Arg(Tos)-Lys(2-ClZ)-Leu)propionyl copoly(styrene-1% divinylbenzene), and its subsequent cleavage to the corresponding C-terminal carboxyl fragment hGRF(16-22)OH
The Boc-amino acid resin of Example 2b (618 9, amine content: 0.805 mmole/g) was used to form the hGRF-(16-22)-resin fragment by a modification of the solid phase technique of R.B. Merrifield, J. Amer. Chem.
Soc., 85, 2149 (1963). The selected Boc-amino acids were added to the growing peptidyl-resin chain by the DCC-HOBT activated acid method (Lys, Arg, Ser, Gln) or by the symmetrical anhydride method (Ala, Leu).
The DCC-HOBT method comprised adding DCC (2 equiv.) in CH2Cl2 to a cold solution of HOBT (2 equiv.) and the selected Boc-amino acid (2 equiv.) in DMF, stirring the mixture at 0~ for 30 min. and adding the mixture to a suspension of the peptidyl resin in CH2Cl2. The symmetrical anhydride method comprised adding DCC (2 equiv.) in CH2Cl2 to the selected Boc-amino acid (4 equiv.) in CH2Cl2 at 0~, stirring the mixture at 0~ for 30 min, filtering the mixture and adding the filtrate to a suspension of the peptidyl resin in CH2Cl2. The coupling cycle consis-ted of i) deprotection with 30% TFA in CH2Cl2 (twice for 5 min, once for 25 min) (ii) neutralization with 5% DIEA in CH2Cl2 (twice for 3 min) and (iii) coupl-ing by addition of symmetrical anhydride or activated ester corresponding to the selected Boc-amino acid.
Intermediate washes were done successively with 17 1~396~1 CH2Cl2, 50~ isopropanol in CH2Cl2, isopropanol and CH2Cl2. The coupling reactions were monitored by the Kaiser tests and the fluorescamin test, see B.F.
Gisin, supra. The time required to complete the coupling reaction ranged from 4 to 24h . The final product was washed with DMF, CH2Cl2' isopropanol, CH2Cl 2 and EtOH, and then dried under vacuum to give 1217.4 g of the hGRF(16-22)-resin (100% yield, 96%
pure by HPLC).
The latter peptidyl resin was subjected to photolysis as follows: The peptidylresin (300g) was suspended in a mixture of DMF (7.5 l) and EtOH (3.9 l) in a Pyrex vessel. The suspension was purged with argon.
While being subjected to a continuous stream of argon, the suspension was stirred and irradiated at 0~ at a wavelength of 350 nm for 70h. The suspension was filtered. The filtrate was concentrated to dryness under reduced pressure at room temperature.
The residual oil was triturated with anhydrous Et20 to give a white solid. The solid was collected, washed with anhydrous Et20 and dried under vacuum over P205 to give 185 g of the corresponding pro-tected N-terminal, free C-terminal carboxyl segment, hGRF (16-22)OH, (100% yield, 95.4% pure by HPLC).
b) Preparation of hGRF(10-15)-resin fragment, 4-[2-(Boc-Tyr(2,6-diClBzl)-Arg(Tos)-Lys(2-ClZ)-Val-Leu-Gly)propionyl]phenoxyacetyl BHA resin, and its subsequent cleavage to the corresponding C-terminal carboxyl fragment hGRF(10-15)OH
The hGRF(10-15)-resin was assembled with the appropriate Boc-amino acids in the same manner as described for the preceding peptidylresin, using the symmetrical anhydride method (Leu ,Val ) and the DCC-HOBT method (Lys, Arg,Tyr) and the Boc-Amino acid ~ -~ ~ .
1~9~31 resin of Example 2c (574 g, amine content: 0.45 mmole/g) as a starting material. Thus, the hGRF(10-15)-resin (933 g) was obtained (100% yield).
The latter peptidylresin (466 g) was subjected to photolysis in the manner described for the preceding peptidylresin of Example 3a to give 161 g of the cor-responding protected N-terminal, free C-terminal carboxyl segment, hGRF(10-15)0H (87% yield, 97% pure by HPLC).
In the same manner but replacing the Boc-amino acid resin of Example 2c with an equivalent amount of 2-(Boc-glycyl)propionyl copoly(styrene-1% divinylben-zene) of Example 2a, h-GRF(10-15)0H also was obtained.
Example 4 Preparation of protected hGRF(1-29)-resin By following the solid phase technique described in Example 3, the fragment hGRF(23-29) was assembled on a BHA resin. The appropriate Boc-amino acids were coupled by the DCC-HOBT method (Arg, Ser, Gln) or by the symmetrical anhydride method (Met, Ile, Asp, Leu). The t-butylcarbocation scavenger, DL-methion-ine (1% by volume of the scavanger in 30% TFA-CH2Cl2 solution), was used during Boc-deprotection following the coupling of Met, Ile, Asp and Gln, cf. D.
Le-Nguyen et al., J. Chem. Soc. Perkin Trans., 1, 1915 (1987). On completion of coupling the Leu residue to the growing peptide-resin, the resultant h G R F ( 2 3 - 2 9 ) - r e s i n , i . e .
Boc-Leu-Gln-Asp(Chxl)-Ile-Met-Ser(Bzl)-Arg(Tos)-BHA, was coupled serially (DCC-HOBT method) with the pro-1 9 1 ~ 3 '~
tected fragments of hGRF(16-22)OH and hGRF(10-15)OH
of Examples 3a and 3b, respectively. (For the depro-tection steps prior to the latter two couplings, and for all subsequent deprotection steps of this examp-le, DL-methionine was used as a scavenger.) There-after, the resultant hGRF(10-29)-resin was coupled stepwise with the appropriate Boc-amino acids, using the DCC-HOBT method for coupling Ser, Asn and Tyr, and the symmetrical anhydride method for Thr, Phe, Ile, Ala, Met and Asp. Following a final deprotect-ion (30% TFA in CH2Cl2 plus 1% by volume of DL-methi-onine), the protected hGRF(1-29)-resin, i.e. H-Tyr-(2,6-diClBzl)-Ala-Asp(Chxl)-Ala-Ile-Phe-Thr(Bzl)-Asn-Ser(Bzl)-Tyr(2,6-diClBzl)-Arg(Tos)-Lys(2-ClZ)-Val-Leu-Gly-Gln-Leu-Ser(Bzl)-Ala-Arg(Tos)-Lys(2-ClZ)-Leu-Leu-Gln-Asp(Chxl)-Ile-Met-Ser(Bzl)-Arg(Tos)-BHA
(124.45 g, 91% yield) was obtained.
Example 5 Preparation of hGRF(1-29)NH2 A mixture of the preceding protected hGRF(1-29)-resin (75.9g), DL-methionine (7.6 g) and anisole (distil-led, 75ml) was placed under nitrogen (positive pres-sure). The mixture was cooled at -80~ for 10 min (dry ice-isopropanol bath). Anhydrous hydrogen fluoride was distilled slowly into the cooled mixture over a period of about 70 min. The total amount of hydrogen fluoride added to the mixture was 750 ml.
The reaction mixture was stirred at 0~ for lh under nitrogen. Thereafter, a stream of nitrogen was passed immediately over the reaction vessel at 20-22~
until most of the hydrogen fluoride had evaporated.
The residue was dried under high vacuum for 100 min and then extracted with TFA (700 ml). The extract was concentrated to a small volume. Dilution of the concentrate with Et20 afforded a solid. The solid was collected, washed with Et20 and dried under high vacuum to give 44.7 9 of the crude title compound (TFA salt).
A portion of the latter crude product (4.0g) was purified further by HPLC (Sep Tech 1200, 5 x 35 cm;
Vydac ODS, 15-20~ particle size; 300 nm; linear gradient, 100ml/min, solvent A: 0.06% TFA in water, solvent B: 0.06% TFA in acetonitrile). The appropriate fractions were combined. Acetonitrile was removed under vacuum. The residue was lyophi-lized to give hGRF(1-29)NH2 (662 mg, 16.5% yield, 98.4% pure as indicated by HPLC).
Claims (8)
1. A process for preparing hGRF(1-29)NH2 which comprises:
(a) stepwise coupling the required amino acid residues to the amino acid-resin of formula H-Gly-S-P
wherein S is and P is benzhydrylamine resin or S is -CH(CH3CO- and P is a styrene-divinylbenzene resin, to obtain the hGRF(10-15)- resin of formula 2 X-Tyr(W1)-Arg(W2)-Lys(W3)-Val-Leu-Gly-S-P 2 wherein X is an .alpha.-amino protective group, W1, W2 and W3 are protective groups, and S and P are as described hereinabove; and cleaving the hGRF(10-15)-resin by photolysis to obtain the corresponding hGRF(10-15)OH
fragment of formula 3 X-Tyr(W1)-Arg(W2)-Lys(W3)-Val-Leu-Gly-OH 3 wherein X, W1, W2 and W3 are as described hereinabove;
(b) stepwise coupling the required amino acid residues to the amino acid-resin of formula H-Leu-S-P wherein S
and P are as defined hereinabove to obtain the hGRF((16-22)-resin of formula 4 X-Gln-Leu-Ser(W4)-Ala-Arg(W2)-Lys(W3)-Leu-S-P 4 wherein X is an a-amino protective group, W2, W3, S and P are as defined hereinabove, and W4 is a protective group; and cleaving the hGRF(16-22)-resin by photolysis to obtain the corresponding hGRF(16-22)OH fragment of formula 5 X-Gln-Leu-Ser(W4)-Ala-Arg(W2)-Lys(W3)-Leu-OH 5 in which X is an .alpha.-amino protective group and W2, W3, and W are as defined hereinabove;
(c) coupling stepwise a hGRF (23-29)-resin of formula H-Leu-Gln-Asp(W5)-Ile-Met-Ser(W4)-Arg(W2)-Q 6 wherei n W2, W4 and W5 are protective groups and Q is a benzhydrylamine type resin, with the previously noted hGRF(16-22)OH fragment of formula 5 and the hGRF(10-15)OH fragment of formula 3 to obtain a hGRF(10-29)-resin of formula 7 X-Tyr(W1)-Arg(W2)-Lys(W3)-val-Leu-Gly-Gln-Leu-Ser(W4)-Ala-Arg(W2)-Lys(W3)-Leu-Leu-Gln- 7 Asp(W5)-Ile-Met-Ser(W4)-Arg(W2)-Q
wherein X, W1, W2, W3, W4, W5 and Q are as defined hereinabove;
(d) selectiviely removing the .alpha.-amino protective group of the hGRF(10-29)-resi n to obtai n the corresponding hGRF(10-29)-resin of formula 7 wherein X is hydrogen;
(e) coupling stepwise the last-named hGRF(10-29)-resin with the required amino acid residues to obtain the hGRF(1-29)-resin of formula 8 X-Tyr(W1)-Ala-Asp(W5)-Ala-Ile-Phe-Thr(W6)-Asn-Ser(W4)-Tyr(W1)-Arg(W2)-Lys(W3)-Val-Leu- 8 Gly-Gln-Leu-Ser(W4)-Ala-Arg(W2)-Lys(W3)-Leu-Leu-Gln-Asp(W5)-Ile-Met-Ser(W4)-Arg(W2)-Q
wherein X is an .alpha.-amino protective group, W1, W2, W3, W4 and W5 and Q are as defined hereinabove, and W6 is a protective group; and (f) deprotecting the hGRF(1-29)-resin of formula 8 to obtain hGRF(1-29)NH2.
(a) stepwise coupling the required amino acid residues to the amino acid-resin of formula H-Gly-S-P
wherein S is and P is benzhydrylamine resin or S is -CH(CH3CO- and P is a styrene-divinylbenzene resin, to obtain the hGRF(10-15)- resin of formula 2 X-Tyr(W1)-Arg(W2)-Lys(W3)-Val-Leu-Gly-S-P 2 wherein X is an .alpha.-amino protective group, W1, W2 and W3 are protective groups, and S and P are as described hereinabove; and cleaving the hGRF(10-15)-resin by photolysis to obtain the corresponding hGRF(10-15)OH
fragment of formula 3 X-Tyr(W1)-Arg(W2)-Lys(W3)-Val-Leu-Gly-OH 3 wherein X, W1, W2 and W3 are as described hereinabove;
(b) stepwise coupling the required amino acid residues to the amino acid-resin of formula H-Leu-S-P wherein S
and P are as defined hereinabove to obtain the hGRF((16-22)-resin of formula 4 X-Gln-Leu-Ser(W4)-Ala-Arg(W2)-Lys(W3)-Leu-S-P 4 wherein X is an a-amino protective group, W2, W3, S and P are as defined hereinabove, and W4 is a protective group; and cleaving the hGRF(16-22)-resin by photolysis to obtain the corresponding hGRF(16-22)OH fragment of formula 5 X-Gln-Leu-Ser(W4)-Ala-Arg(W2)-Lys(W3)-Leu-OH 5 in which X is an .alpha.-amino protective group and W2, W3, and W are as defined hereinabove;
(c) coupling stepwise a hGRF (23-29)-resin of formula H-Leu-Gln-Asp(W5)-Ile-Met-Ser(W4)-Arg(W2)-Q 6 wherei n W2, W4 and W5 are protective groups and Q is a benzhydrylamine type resin, with the previously noted hGRF(16-22)OH fragment of formula 5 and the hGRF(10-15)OH fragment of formula 3 to obtain a hGRF(10-29)-resin of formula 7 X-Tyr(W1)-Arg(W2)-Lys(W3)-val-Leu-Gly-Gln-Leu-Ser(W4)-Ala-Arg(W2)-Lys(W3)-Leu-Leu-Gln- 7 Asp(W5)-Ile-Met-Ser(W4)-Arg(W2)-Q
wherein X, W1, W2, W3, W4, W5 and Q are as defined hereinabove;
(d) selectiviely removing the .alpha.-amino protective group of the hGRF(10-29)-resi n to obtai n the corresponding hGRF(10-29)-resin of formula 7 wherein X is hydrogen;
(e) coupling stepwise the last-named hGRF(10-29)-resin with the required amino acid residues to obtain the hGRF(1-29)-resin of formula 8 X-Tyr(W1)-Ala-Asp(W5)-Ala-Ile-Phe-Thr(W6)-Asn-Ser(W4)-Tyr(W1)-Arg(W2)-Lys(W3)-Val-Leu- 8 Gly-Gln-Leu-Ser(W4)-Ala-Arg(W2)-Lys(W3)-Leu-Leu-Gln-Asp(W5)-Ile-Met-Ser(W4)-Arg(W2)-Q
wherein X is an .alpha.-amino protective group, W1, W2, W3, W4 and W5 and Q are as defined hereinabove, and W6 is a protective group; and (f) deprotecting the hGRF(1-29)-resin of formula 8 to obtain hGRF(1-29)NH2.
2. A process of claim 1 wherein W1 is 2,6-dichloro-benzyl, W2 is tosyl, W3 is 2-chlorobenzyloxycarbonyl, W4 is benzyl, W5 is cyclohexyl and W6 is benzyl.
3. A process of claim 1 wherein X is benzyloxycarbonyl.
4. A process of claim 1 wherein S and P of the amino acid-resin of formula H-Gly-S-P and the h-GRF(10-15)- resin of formula 2 is and benzylhydrylamine resin, respectively; S and P of the amino acid-resin of formula H-Leu-S-P and the hGRF(16-22)-resin of formula 4 is -CH(CH3)CO- and a styrene-divinylbenzene resin, respectively; and X is benzyloxycarbonyl.
5. A hGRF(10-15)-resin of formula 2 of claim 1.
6. A hGRF(10-15)-resin of formula 2 of claim wherein S is and P is benzylhydrylamine resin.
7. A hGRF(16-22)-resin of formula 4 of claim 1.
8. A hGRF(16-22)-resin of formula 4 of claim 1 wherein S is -CH(CH3)CO- and P is styrene-divinylbenzene resin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA000579916A CA1339631C (en) | 1988-10-12 | 1988-10-12 | Process and intermediates for grf peptide |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA000579916A CA1339631C (en) | 1988-10-12 | 1988-10-12 | Process and intermediates for grf peptide |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1339631C true CA1339631C (en) | 1998-01-20 |
Family
ID=4138895
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000579916A Expired - Fee Related CA1339631C (en) | 1988-10-12 | 1988-10-12 | Process and intermediates for grf peptide |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA1339631C (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112175066A (en) * | 2020-10-26 | 2021-01-05 | 浙江苏泊尔制药有限公司 | Method for preparing sertraline |
-
1988
- 1988-10-12 CA CA000579916A patent/CA1339631C/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112175066A (en) * | 2020-10-26 | 2021-01-05 | 浙江苏泊尔制药有限公司 | Method for preparing sertraline |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4607023A (en) | Natriuretic | |
US7348404B2 (en) | Solid-phase peptide synthesis and agent for use in such synthesis | |
AU662731B2 (en) | Growth hormone releasing factor analogs | |
CA2024855C (en) | Process and intermediates for producing glucagon | |
SU1651787A3 (en) | Method for preparation of polypeptide with properties of factor release of growth hormone | |
US4786684A (en) | Benzylthioether-linked solid support-bound thiol compounds and method for peptide synthesis | |
JP2891882B2 (en) | Human relaxin H2 gene | |
KR20110056536A (en) | Process for the preparation of pramlintide | |
AU598507B2 (en) | Peptides with vasorelaxant, natriuretic and diuretic effects, a process for their preparation, agents containing them, and their use | |
EP1179537B1 (en) | Solid phase peptide synthesis method | |
JPS62116595A (en) | Novel compound, its production and pharmaceutical composition containing the same | |
DK161835B (en) | GRF ANALOGUE PEPTIDES AND PHARMACEUTICAL ACCEPTABLE SALTS THEREOF AND SUBSTANCE CONTAINING THESE | |
JPS62283997A (en) | Synthetic sodium discharge increasing peptides | |
CA1339631C (en) | Process and intermediates for grf peptide | |
US7176282B1 (en) | Solid-phase peptide synthesis and agent for use in such synthesis | |
GB1590645A (en) | Process for preparing hentriacontapeptide having activity in reducing blood calcium levels | |
GB1590668A (en) | Process for the preparation of thymosin a1 and an analogue | |
US4427827A (en) | Synthesis of hormone fragments | |
US4959352A (en) | Cyclic growth hormone releasing factor analogs and method for the manufacture thereof | |
CA1335403C (en) | Process and intermediates for lh-rh peptides | |
CA1339700C (en) | Process and entermediates for anf peptide | |
EP0056274A1 (en) | Indole derivatives and a method for production of peptides | |
JPH06336496A (en) | Cyclic hexapeptide, its production and production of cyclic peptide | |
US5502164A (en) | Peptide compounds having therapeutic activity | |
CN115433266A (en) | Solid-phase synthesis method of teriparatide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKLA | Lapsed |